 Katherine Rennie
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hair Cells, Vestibular | 19 | 2020 | 26 | 5.470 |
Why?
| | Potassium | 10 | 2014 | 149 | 1.960 |
Why?
| | Potassium Channels | 7 | 2016 | 135 | 1.710 |
Why?
| | Action Potentials | 8 | 2020 | 455 | 1.690 |
Why?
| | Gerbillinae | 17 | 2020 | 64 | 1.430 |
Why?
| | Sodium | 6 | 2020 | 202 | 1.260 |
Why?
| | Ear, Inner | 2 | 2016 | 32 | 1.120 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2017 | 99 | 1.050 |
Why?
| | Neurons, Afferent | 3 | 2016 | 99 | 0.930 |
Why?
| | Membrane Potentials | 11 | 2016 | 255 | 0.910 |
Why?
| | Tetrodotoxin | 2 | 2020 | 44 | 0.900 |
Why?
| | Sodium Channel Blockers | 2 | 2020 | 26 | 0.890 |
Why?
| | Ion Channels | 3 | 2012 | 131 | 0.890 |
Why?
| | Patch-Clamp Techniques | 12 | 2016 | 256 | 0.870 |
Why?
| | Sarcopenia | 1 | 2022 | 59 | 0.850 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2020 | 8 | 0.810 |
Why?
| | Vestibular Nerve | 1 | 2020 | 17 | 0.810 |
Why?
| | Frailty | 1 | 2022 | 86 | 0.800 |
Why?
| | Nose Deformities, Acquired | 1 | 2020 | 2 | 0.790 |
Why?
| | Nasal Septum | 1 | 2020 | 16 | 0.780 |
Why?
| | Resistance Training | 1 | 2022 | 120 | 0.780 |
Why?
| | Rhinoplasty | 1 | 2020 | 16 | 0.770 |
Why?
| | Nasal Obstruction | 1 | 2020 | 25 | 0.760 |
Why?
| | Conservative Treatment | 1 | 2020 | 34 | 0.750 |
Why?
| | Receptors, AMPA | 2 | 2017 | 115 | 0.710 |
Why?
| | Metformin | 1 | 2022 | 291 | 0.700 |
Why?
| | Presynaptic Terminals | 2 | 2011 | 56 | 0.700 |
Why?
| | Semicircular Canals | 5 | 2009 | 28 | 0.690 |
Why?
| | Potassium Channel Blockers | 5 | 2014 | 42 | 0.660 |
Why?
| | Sodium Channels | 2 | 2009 | 72 | 0.650 |
Why?
| | Vestibule, Labyrinth | 4 | 2016 | 49 | 0.610 |
Why?
| | Hair Cells, Auditory | 5 | 2016 | 32 | 0.590 |
Why?
| | Hair Cells, Auditory, Inner | 2 | 2009 | 12 | 0.530 |
Why?
| | Neomycin | 1 | 2013 | 8 | 0.500 |
Why?
| | Gentamicins | 1 | 2013 | 31 | 0.500 |
Why?
| | Anthracenes | 3 | 2014 | 31 | 0.470 |
Why?
| | Apamin | 1 | 2011 | 6 | 0.450 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 9 | 0.440 |
Why?
| | Synapses | 2 | 2017 | 332 | 0.430 |
Why?
| | Hair Cells, Ampulla | 1 | 2010 | 2 | 0.400 |
Why?
| | Animals | 28 | 2020 | 34350 | 0.380 |
Why?
| | Calcium | 5 | 2011 | 1203 | 0.360 |
Why?
| | Mechanotransduction, Cellular | 2 | 2014 | 104 | 0.350 |
Why?
| | Columbidae | 7 | 2004 | 31 | 0.350 |
Why?
| | 4-Aminopyridine | 6 | 2014 | 21 | 0.350 |
Why?
| | Cations | 2 | 2016 | 71 | 0.340 |
Why?
| | Ion Channel Gating | 2 | 2005 | 91 | 0.330 |
Why?
| | Cell Membrane | 2 | 2016 | 728 | 0.300 |
Why?
| | Cells, Cultured | 6 | 2017 | 4191 | 0.300 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1209 | 0.280 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2005 | 48 | 0.280 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1422 | 0.250 |
Why?
| | Physical Stimulation | 1 | 2004 | 107 | 0.250 |
Why?
| | Models, Neurological | 2 | 2005 | 251 | 0.240 |
Why?
| | Electric Conductivity | 5 | 2004 | 91 | 0.210 |
Why?
| | Steroids, Fluorinated | 1 | 2020 | 1 | 0.200 |
Why?
| | Wales | 1 | 2020 | 18 | 0.200 |
Why?
| | Scotland | 1 | 2020 | 14 | 0.200 |
Why?
| | England | 1 | 2020 | 56 | 0.200 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 83 | 0.190 |
Why?
| | Administration, Intranasal | 1 | 2020 | 86 | 0.190 |
Why?
| | Double-Blind Method | 2 | 2022 | 1695 | 0.190 |
Why?
| | Electrophysiology | 5 | 2009 | 211 | 0.180 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 232 | 0.180 |
Why?
| | Indoles | 1 | 2001 | 332 | 0.170 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 10 | 0.160 |
Why?
| | Benzothiadiazines | 1 | 2017 | 5 | 0.160 |
Why?
| | Strontium | 1 | 2017 | 12 | 0.160 |
Why?
| | Endoscopy | 1 | 2020 | 255 | 0.160 |
Why?
| | Nifedipine | 1 | 2017 | 31 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 285 | 0.160 |
Why?
| | Pyridines | 1 | 2001 | 471 | 0.160 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 553 | 0.160 |
Why?
| | Dipeptides | 1 | 2017 | 51 | 0.160 |
Why?
| | Quinoxalines | 1 | 2017 | 67 | 0.150 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 112 | 0.150 |
Why?
| | DNA, Mitochondrial | 2 | 2009 | 174 | 0.150 |
Why?
| | Female | 11 | 2020 | 63249 | 0.150 |
Why?
| | Ranidae | 1 | 2016 | 15 | 0.150 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 111 | 0.150 |
Why?
| | Chick Embryo | 1 | 2016 | 146 | 0.150 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 51 | 0.140 |
Why?
| | Coculture Techniques | 1 | 2016 | 200 | 0.140 |
Why?
| | Patient Selection | 1 | 2020 | 698 | 0.140 |
Why?
| | Neurotransmitter Agents | 1 | 2016 | 81 | 0.140 |
Why?
| | Fishes | 1 | 2016 | 80 | 0.140 |
Why?
| | Self Report | 1 | 2020 | 715 | 0.140 |
Why?
| | Male | 8 | 2020 | 60403 | 0.140 |
Why?
| | Acetylcholine | 1 | 2016 | 204 | 0.140 |
Why?
| | Birds | 1 | 2016 | 96 | 0.140 |
Why?
| | Elapid Venoms | 1 | 2014 | 17 | 0.140 |
Why?
| | Beta vulgaris | 1 | 2014 | 4 | 0.140 |
Why?
| | Calcium Channels | 1 | 2016 | 161 | 0.140 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 70 | 0.130 |
Why?
| | Nitrates | 1 | 2014 | 77 | 0.130 |
Why?
| | Phytotherapy | 1 | 2014 | 66 | 0.130 |
Why?
| | Choline | 1 | 2014 | 110 | 0.130 |
Why?
| | Carrier Proteins | 1 | 1997 | 759 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 289 | 0.120 |
Why?
| | Saccule and Utricle | 3 | 2004 | 4 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 3223 | 0.110 |
Why?
| | Cyclic GMP | 1 | 2012 | 110 | 0.110 |
Why?
| | Bee Venoms | 1 | 2011 | 9 | 0.110 |
Why?
| | Cesium | 3 | 2000 | 18 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2884 | 0.110 |
Why?
| | Cyclic AMP | 1 | 2012 | 270 | 0.110 |
Why?
| | Adenosine Triphosphate | 1 | 1993 | 447 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2014 | 465 | 0.100 |
Why?
| | Nitric Oxide | 1 | 2016 | 869 | 0.100 |
Why?
| | Guinea Pigs | 3 | 1997 | 158 | 0.100 |
Why?
| | Animals, Newborn | 1 | 2011 | 846 | 0.090 |
Why?
| | Pyrimidines | 1 | 2012 | 400 | 0.090 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 67 | 0.090 |
Why?
| | Quality of Life | 1 | 2020 | 2354 | 0.090 |
Why?
| | Embryonic Stem Cells | 1 | 2009 | 110 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 337 | 0.080 |
Why?
| | Blood Pressure | 1 | 2014 | 1680 | 0.080 |
Why?
| | In Vitro Techniques | 3 | 1994 | 1143 | 0.070 |
Why?
| | NADH Dehydrogenase | 1 | 2006 | 18 | 0.070 |
Why?
| | Acidosis, Lactic | 1 | 2006 | 27 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2020 | 9353 | 0.070 |
Why?
| | Hypertension | 1 | 2014 | 1202 | 0.070 |
Why?
| | Humans | 6 | 2022 | 117635 | 0.070 |
Why?
| | Point Mutation | 1 | 2006 | 235 | 0.070 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2004 | 35 | 0.070 |
Why?
| | Tetraethylammonium Compounds | 2 | 1996 | 11 | 0.060 |
Why?
| | Mice | 3 | 2016 | 15537 | 0.060 |
Why?
| | Turtles | 1 | 2004 | 14 | 0.060 |
Why?
| | Aged | 1 | 2022 | 20249 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2004 | 557 | 0.060 |
Why?
| | Mitochondria | 1 | 2009 | 823 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2009 | 1791 | 0.050 |
Why?
| | Capsaicin | 1 | 2001 | 27 | 0.050 |
Why?
| | Obesity | 1 | 2014 | 2711 | 0.050 |
Why?
| | Neurons | 1 | 2009 | 1421 | 0.050 |
Why?
| | Rats | 1 | 2009 | 6016 | 0.050 |
Why?
| | Computer Simulation | 1 | 2005 | 923 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2001 | 227 | 0.050 |
Why?
| | Cell Division | 1 | 2001 | 789 | 0.050 |
Why?
| | Adult | 2 | 2020 | 32120 | 0.050 |
Why?
| | Aging | 1 | 2009 | 1690 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1897 | 0.040 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 1997 | 9 | 0.040 |
Why?
| | Cell Separation | 3 | 1997 | 309 | 0.040 |
Why?
| | Chlorides | 1 | 1997 | 137 | 0.040 |
Why?
| | Kinetics | 2 | 1997 | 1686 | 0.040 |
Why?
| | Feeder Cells | 1 | 2016 | 1 | 0.040 |
Why?
| | Species Specificity | 2 | 1997 | 594 | 0.040 |
Why?
| | Mammals | 1 | 1997 | 214 | 0.040 |
Why?
| | Clone Cells | 1 | 2016 | 244 | 0.040 |
Why?
| | Heterografts | 1 | 2016 | 127 | 0.040 |
Why?
| | Posture | 1 | 1996 | 189 | 0.030 |
Why?
| | Plant Preparations | 1 | 2014 | 21 | 0.030 |
Why?
| | Plant Roots | 1 | 2014 | 34 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 453 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2527 | 0.030 |
Why?
| | Beverages | 1 | 2014 | 66 | 0.030 |
Why?
| | Barium | 1 | 1994 | 26 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2014 | 65 | 0.030 |
Why?
| | Fura-2 | 1 | 1993 | 22 | 0.030 |
Why?
| | Electrodes | 1 | 1994 | 88 | 0.030 |
Why?
| | Vegetables | 1 | 2014 | 121 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1012 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1994 | 302 | 0.030 |
Why?
| | Tetraethylammonium | 1 | 1991 | 16 | 0.030 |
Why?
| | Cadmium | 1 | 1991 | 55 | 0.030 |
Why?
| | Hybrid Cells | 1 | 2009 | 49 | 0.020 |
Why?
| | Electron Transport | 1 | 2009 | 106 | 0.020 |
Why?
| | Neurogenesis | 1 | 2009 | 111 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 2009 | 243 | 0.020 |
Why?
| | Body Mass Index | 1 | 2014 | 2076 | 0.020 |
Why?
| | Electron Transport Complex I | 1 | 2006 | 38 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2006 | 109 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2006 | 137 | 0.020 |
Why?
| | Aortic Coarctation | 1 | 2006 | 62 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 305 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2006 | 397 | 0.020 |
Why?
| | Avian Proteins | 1 | 2004 | 21 | 0.020 |
Why?
| | Cricetulus | 1 | 2004 | 105 | 0.020 |
Why?
| | CHO Cells | 1 | 2004 | 147 | 0.020 |
Why?
| | Cricetinae | 1 | 2004 | 273 | 0.020 |
Why?
| | Organ Specificity | 1 | 2004 | 281 | 0.020 |
Why?
| | Oocytes | 1 | 2004 | 217 | 0.020 |
Why?
| | Streptomycin | 1 | 2001 | 16 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2171 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 2106 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2898 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2009 | 3799 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5136 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 3409 | 0.010 |
Why?
| | RNA | 1 | 2004 | 788 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 2832 | 0.010 |
Why?
| | Cochlea | 1 | 1997 | 90 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 5230 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 28661 | 0.010 |
Why?
| | Infant | 1 | 2006 | 8255 | 0.010 |
Why?
| | Homeostasis | 1 | 1996 | 587 | 0.010 |
Why?
|
|
Rennie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|